You are here
The Pricing Framework for Australian Public Hospital Services 2021–22 (the Pricing Framework) is the key strategic document underpinning the national efficient price (NEP) and national efficient cost (NEC) Determinations for the financial year 2021–22 (NEP21 and NEC21 respectively).
The Pricing Framework for Australian Public Hospital Services 2020-21 (the Pricing Framework) is the key strategic document underpinning the National Efficient Price (NEP) and National Efficient Cost (NEC) Determinations for the financial year 2020-21.
IHPA has issued the Pricing Framework prior to releasing the NEP20 and NEC20 Determinations, which will be publicly available in March 2020, with the intention of providing an additional layer of transparency and accountability.
There is a growing discussion in Australia and internationally about the need to increase focus on delivering value-based health care with a focus on patient outcomes and experience.
IHPA’s Pricing Guidelines and the National Health Reform Agreement include provisions for IHPA to consider the impact on its work of evidence‑based, effective new technologies and innovations in models of health care.
The Independent Hospital Pricing Authority (IHPA) is currently developing a new classification for non-admitted care - the Australian Non-Admitted Care Classification (ANACC) - in response to the recommendations of public consultations in 2013 and 2014 on non-admitted care classification.
The Pricing Framework for Australian public hospital services 2019-20 builds on the seven Pricing Frameworks from previous years. The Pricing Framework is the key strategic document underpinning the National Efficient Price (NEP) and National Efficient Cost (NEC) Determinations for the financial year 2019-20.
The purpose of this costing study was to undertake a Teaching, Training and Research (TTR) cost and activity data collection at a representative sample of Australian hospitals and produce costed data to inform the development of a TTR classification.
The purpose of this costing study was to undertake an analysis of CALD patients to inform a policy decision for whether an adjustment is warranted to the National Efficient Price for CALD patients.
The non-admitted study was comprehensive across a range of settings (e.g. outpatients, community and satellite clinics). Similarly all service streams were included regardless of funding source. This ensured that all services were accounted for and costed appropriately providing an accurate cost of delivering multiple services across multiple settings (e.g. overhead costs are apportioned across all patients).
The purpose of this report is to review the costs of providing care to Indigenous patients accessing public hospital services. This work was commissioned in response to stakeholder concerns that the national activity based funding system does not adequately reflect Indigenous patient costs.
Home Enteral Nutrition, Home Total Parenteral Nutrition and Home Ventilation Services Costing Study Report16 January 2015
The Costing study on Home Enteral Nutrition, Home Total Parenteral Nutrition and Home Ventilation Services was undertaken in 2014. The purpose of the study was to review the costs associated with the delivery of public hospital services to patients receiving home enteral nutrition, home total parenteral nutrition and home ventilation services. The study include a literature review, stakeholder consultation and costing the respective services based on data collected from the jurisdictions.
The costing study on home delivered dialysis was undertaken in 2014. The purpose of the study was to collate and compare the range of costing studies and economic evaluations that have been carried out on these services over the past decade.
The report identifies two key studies - NSW Dialysis Costing Study, conducted in 2008, and Queensland Health Renal Replacement Therapy Costing Study, conducted in 2008 - which are useful in estimating the current costs of home-based dialysis.
PwC and its sub-contractor The Independent Hospital Pricing Authority (IHPA) engaged PwC and its sub-contractor SyRis Consulting to undertake a review and costing study of Australian radiotherapy services. The study was commissioned to determine the reliability of radiotherapy cost data due to its role in the development of associated price weights in both admitted and non-admitted settings.